Omicron variant

Infections, like all biological phenomena, change and evolve. The poorly-defined Post-Acute Sequelae of COVID (PASC), or “Long COVID,” is no exception. A new study reports on the dynamic incidence of Long COVID over time.

The new booster, available since September, is effective against the currently dominant SARS-CoV-2 variant in the U.S., JN.1.

Many corporations have suspended operations in Russia. Many have been lauded as having an ethical compass. But I wonder whether this behavior, especially concerning medications, will come back to bite us?

It cannot be the least bit surprising that there is another Covid variant in the news.

Let’s begin with the limitations. It is a small study, still in preprint (not peer-reviewed) and looking at patients that are acutely symptomatic but not requiring hospitalization.

If you've been closely following the pandemic from the beginning (I hope you're enjoying the Prozac), it should be obvious how little we really knew about COVID a year ago. Social distancing? Did it really work? Maybe.

Consider these recent headlines and imagine how they were interpreted by casual news followers.